HYBENFI

Class [005]
Pharmaceutical preparations and substances for the treatment of gastrointestinal diseases; pharmaceutical preparations for diagnosing and treating neurodegenerative diseases; pharmaceutical preparations for the prevention and treatment of cancer; pharmaceutical preparations for the prevention and treatment of cardiovascular diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of metabolic diseases and disorders, namely diabetes, gout, arthritis and anemia; pharmaceutical preparations for the prevention and treatment of metabolic disorders, namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome; pharmaceutical preparations for the treatment and prevention of migraines, headaches and pain; pharmaceutical preparations for the treatment and the prevention of dementia; pharmaceutical preparations for the treatment of alopecia and androgenic alopecia; pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of bone diseases; pharmaceutical preparations for the treatment of central nervous system [CNS] diseases; pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; pharmaceutical preparations for the treatment of dermatological diseases and disorders namely dermatitis, skin and bacterial skin infections and fungal skin infections; pharmaceutical preparations for the treatment of dermatological diseases and disorders namely fungal skin infections, viral skin infections and parasitic skin infections, psoriasis, eczema, and sexually transmitted diseases; pharmaceutical preparations for the treatment of digestive diseases and disorders, namely, Crohn's disease, irritable bowel syndrome; pharmaceutical preparations for the treatment of digestive diseases and disorders, namely, ulcerative colitis; pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders, and neuromuscular diseases, namely primary periodic paralysis; pharmaceutical preparations for the treatment of endocrine diseases, namely, glucagonoma; pharmaceutical preparations for the treatment of headaches; pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations for the treatment of immunologic diseases and disorders namely, autoimmune diseases and disorders; pharmaceutical preparations for the treatment of inflammation and inflammatory diseases, namely inflammatory bowel diseases, inflammatory connective tissue diseases, inflammatory pelvic diseases; pharmaceutical preparations for the treatment of kidney diseases and disorders; pharmaceutical preparations for the treatment of liver diseases and disorders; pharmaceutical preparations for the treatment of mental health disorders; pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely diabetes, hypoglycemia, gout, osteoarthritis, muscular dystrophy, anemia; pharmaceutical preparations for the treatment of metabolic disorders, namely diabetes, bulimia nervosa, anorexia, obesity and hypothyroidism; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for the treatment of musculoskeletal disorders; pharmaceutical preparations for the treatment of neurological diseases, namely, Alzheimer's, Huntington's Disease, cerebral palsy; pharmaceutical preparations for the treatment of neurological diseases, namely, myasthenia gravis; pharmaceutical preparations for the treatment of neurological diseases, namely, myasthenia gravis, Alzheimer's, Huntington's Disease, cerebral palsy; pharmaceutical preparations for the treatment of neurological disorders, namely, brain injury, spinal cord injury, seizure disorders; pharmaceutical preparations for the treatment of obesity; pharmaceutical preparations for the treatment of Parkinson's disease; pharmaceutical preparations for the treatment of the central nervous system, namely, encephalitis, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease; pharmaceutical preparations for the treatment of vascular diseases; pharmaceutical preparations for treatment of coronavirus;